Recent changes to adult national immunization programs for pneumococcal vaccination in Europe and how they impact coverage: A systematic review of published and grey literature

References

• Drijkoningen JJ, Rohde GG. Pneumococcal infection in adults: burden of disease. Clin Microbiol Infect. 2014;20(Suppl 5):45–13. doi:10.1111/1469-0691.12461.
   PubMed Web of Science ®Google Scholar
• Chalmers JD, Campling J, Dicker A, Woodhead M, Madhava H. A systematic review of the burden of vaccine preventable pneumococcal disease in UK adults. BMC Pulm Med. 2016;16(1):77. doi:10.1186/s12890-016-0242-0.
   PubMed Web of Science ®Google Scholar
• Navarro-Torné A, Montuori EA, Kossyvaki V, Méndez C. Burden of pneumococcal disease among adults in Southern Europe (Spain, Portugal, Italy, and Greece): a systematic review and meta-analysis. Hum Vaccin Immunother. 2021;17(10):3670–86. doi:10.1080/21645515.2021.1923348.
   PubMed Web of Science ®Google Scholar
• Ceyhan M, Dagan R, Sayiner A, Chernyshova L, Dinleyici E, Hryniewicz W, Kulcsár A, Mad’arová L, Pazdiora P, Sidorenko S, et al. Surveillance of pneumococcal diseases in central and Eastern Europe. Hum Vaccin Immunother. 2016;12(8):2124–34. doi:10.1080/21645515.2016.1159363.
   PubMed Web of Science ®Google Scholar
• Center for Disease Control and Prevention (CDC). Global Pneumococcal Disease & Vaccine. 2022. https://www.cdc.gov/pneumococcal/global.html#:~:text=The%20World%20Health%20Organization%20(WHO,cause%20of%20pneumonia%20mortality%20globally.
   Google Scholar
• Blasi F, Mantero M, Santus P, Tarsia P. Understanding the burden of pneumococcal disease in adults. Clin Microbiol Infect. 2012;18(Suppl 5):7–14. doi:10.1111/j.1469-0691.2012.03937.x.
   PubMed Web of Science ®Google Scholar
• Torres A, Cillóniz C, Blasi F, Chalmers JD, Gaillat J, Dartois N, Schmitt HJ, Welte T. Burden of pneumococcal community-acquired pneumonia in adults across Europe: a literature review. Respir Med. 2018;137:6–13. doi:10.1016/j.rmed.2018.02.007.
   PubMed Web of Science ®Google Scholar
• Shoar S, Musher DM. Etiology of community-acquired pneumonia in adults: a systematic review. Pneumonia (Nathan). 2020;12(1):11. doi:10.1186/s41479-020-00074-3.
   PubMedGoogle Scholar
• Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67(1):71–9. doi:10.1136/thx.2009.129502.
   PubMed Web of Science ®Google Scholar
• Paton JC, Trappetti C, Fischetti VA, Novick RP, Ferretti JJ, Portnoy DA, Braunstein M, Rood JI. Streptococcus pneumoniae Capsular Polysaccharide. Microbiol Spectr. 2019;7(2). doi:10.1128/microbiolspec.GPP3-0019-2018.
   Web of Science ®Google Scholar
• Ganaie F, Maruhn K, Li C, Porambo RJ, Elverdal PL, Abeygunwardana C, van der Linden M, Duus JØ, Sheppard CL, Nahm MH, et al. Structural, genetic, and serological elucidation of Streptococcus pneumoniae serogroup 24 serotypes: discovery of a New serotype, 24C, with a variable capsule structure. J Clin Microbiol. 2021;59(7):e0054021. doi:10.1128/JCM.00540-21.
   PubMed Web of Science ®Google Scholar
• Ganaie F, Saad JS, McGee L, van Tonder AJ, Bentley SD, Lo SW, Gladstone RA, Turner P, Keenan JD, Breiman RF, et al. A New pneumococcal capsule type, 10D, is the 100th serotype and has a large cps fragment from an oral Streptococcus. mBio. 2020;11(3). doi:10.1128/mBio.00937-20.
   Web of Science ®Google Scholar
• Musher DM, Anderson R, Feldman C. The remarkable history of pneumococcal vaccination: an ongoing challenge. Pneumonia (Nathan). 2022;14(1):5. doi:10.1186/s41479-022-00097-y.
   PubMedGoogle Scholar
• Izurieta P, Bahety P, Adegbola R, Clarke C, Hoet B. Public health impact of pneumococcal conjugate vaccine infant immunization programs: assessment of invasive pneumococcal disease burden and serotype distribution. Expert Rev Vaccines. 2018;17(6):479–93. doi:10.1080/14760584.2018.1413354.
   PubMed Web of Science ®Google Scholar
• Westerink MA, Schroeder HW Jr., Nahm MH. Immune responses to pneumococcal vaccines in children and adults: rationale for age-specific vaccination. Aging Dis. 2012;3:51–67.
   PubMed Web of Science ®Google Scholar
• Weil-Olivier C, van der Linden M, de Schutter I, Dagan R, Mantovani L. Prevention of pneumococcal diseases in the post-seven valent vaccine era: a European perspective. BMC Infect Dis. 2012;12(1):207. doi:10.1186/1471-2334-12-207.
   PubMedGoogle Scholar
• European Center for Disease Control (ECDC). Annual epidemiological report for 2016: invasive pneumococcal disease. Belgium: ECDC; 2016.
   Google Scholar
• Kobayashi M, Farrar JL, Gierke R, Britton A, Childs L, Leidner AJ, Campos-Outcalt D, Morgan RL, Long SS, Talbot HK, et al. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. Adults: updated recommendations of the advisory committee on immunization practices — United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71(4):109–17. doi:10.15585/mmwr.mm7104a1.
   PubMed Web of Science ®Google Scholar
• Azuma M, Oishi K, Akeda Y, Morino S, Motoki Y, Hanibuchi M, Nishioka Y. Safety and immunogenicity of sequential administration of PCV13 followed by PPSV23 in pneumococcal vaccine-naïve adults aged ≥ 65 years: comparison of booster effects based on intervals of 0.5 and 1.0 year. Vaccine. 2023;41(5):1042–9. doi:10.1016/j.vaccine.2022.12.060.
   PubMed Web of Science ®Google Scholar
• Cripps AW, Folaranmi T, Johnson KD, Musey L, Niederman MS, Buchwald UK. Immunogenicity following revaccination or sequential vaccination with 23-valent pneumococcal polysaccharide vaccine (PPSV23) in older adults and those at increased risk of pneumococcal disease: a review of the literature. Expert Rev Vaccines. 2021;20(3):257–67. doi:10.1080/14760584.2021.1889374.
   PubMed Web of Science ®Google Scholar
• ECDC. Pneumococcal Disease: recommended vaccinations. 2022. https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=25&SelectedCountryIdByDisease=-1.
   Google Scholar
• Nohynek H, Wichmann O, DA F. National advisory groups and their role in immunization policy-making processes in European countries. Clin Microbiol Infect. 2013;19(12):1096–105. doi:10.1111/1469-0691.12315.
   PubMed Web of Science ®Google Scholar
• Córcoles ÁV. Pneumococcal vaccination in times of COVID-19. Med Clin (Engl Ed). 2022;158(8):366–8. doi:10.1016/j.medcle.2022.01.004.
   PubMedGoogle Scholar
• Barman TK, Singh AK, Bonin JL, Nafiz TN, Salmon SL, Metzger DW. Lethal synergy between SARS-CoV-2 and Streptococcus pneumoniae in hACE2 mice and protective efficacy of vaccination. JCI Insight. 2022;7(11). doi:10.1172/jci.insight.159422.
   PubMed Web of Science ®Google Scholar
• Sempere J, Llamosí M, López Ruiz B, Del Río I, Pérez-García C, Lago D, Gimeno M, Coronel P, González-Camacho F, Domenech M, et al. Effect of pneumococcal conjugate vaccines and SARS-CoV-2 on antimicrobial resistance and the emergence of Streptococcus pneumoniae serotypes with reduced susceptibility in Spain, 2004–20: a national surveillance study. Lancet Microbe. 2022;3(10):e744–e52. doi:10.1016/S2666-5247(22)00127-6.
   PubMedGoogle Scholar
• Bencina G, Fues Wahl H, Tsoumani E, Salomonsson S. Recommendations and Health Technology Assessment (HTA) landscape evaluation for pediatric pneumococcal conjugate vaccines (PCV) in Europe: A systematic literature review. Hum Vaccin Immunother. 2022;18(5):2060017. doi:10.1080/21645515.2022.2060017.
   PubMed Web of Science ®Google Scholar
• Hu T, Weiss T, Bencina G, Owusu-Edusei K, Petigara T. Health and economic burden of invasive pneumococcal disease associated with 15-valent pneumococcal conjugate vaccine serotypes in children across eight European countries. J Med Econ. 2021;24(1):1098–107. doi:10.1080/13696998.2021.1970975.
   PubMed Web of Science ®Google Scholar
• Huang L, Wasserman M, Grant L, Farkouh R, Snow V, Arguedas A, Chilson E, Sato R, Perdrizet J. Burden of pneumococcal disease due to serotypes covered by the 13-valent and new higher-valent pneumococcal conjugate vaccines in the United States. Vaccine. 2022;40(33):4700–8. doi:10.1016/j.vaccine.2022.06.024.
   PubMed Web of Science ®Google Scholar
• CRD CfRaD. Systematic Reviews - CRD’s guidance for undertaking reviews in health care. 2009.
   Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Bmj. 2021;372:n71. doi:10.1136/bmj.n71.
   PubMed Web of Science ®Google Scholar
• National Immunization Technical Advisory Groups. 2020. https://www.nitag-resource.org/.
   Google Scholar
• International Network of Agencies for Health Technology Assessment (INAHTA). Members List. http://www.inahta.org/members/members_list/.
   Google Scholar
• European Network for Health Technology Assessment EUnetHTA Network. https://eunethta.eu/about-eunethta/eunethtanetwork/.
   Google Scholar
• AEMPS. Consejo interterritorial del sistema nacional de salud vacunación específica en personas adultas (≥18 años) con condiciones de riesgo. 2022.
   Google Scholar
• AIFA. L’uso dei Farmaci in Italia Rapporto Nazionale Anno. 2020.
   Google Scholar
• Alexander Kuhlmann J-MGVDS. Serotype dynamics in pneumococcal diseases and the performance of vaccination strategies for older adults in Germany. 2020.
   Google Scholar
• Agencji Oceny Technologii Medycznych i Taryfikacji (AOTMiT). Opinia Prezesa Agencji Oceny Technologii Medycznych i Taryfikacji nr 25/2021 z dnia 30 kwietnia 2021 r. o projekcie programu polityki zdrowotnej „Program profilaktyki zakażeń pneumokokowych u osób powyżej 65 roku życia”. 2021.
   Google Scholar
• Agencji Oceny Technologii Medycznych i Taryfikacji (AOTMiT). Protokół nr 15/2022 z posiedzenia Rady Przejrzystości. 2022.
   Google Scholar
• Bauer A, Tiefengraber D, Wiedermann U. Towards understanding vaccine hesitancy and vaccination refusal in Austria. Wien Klin Wochenschr. 2021;133(13):703–13. doi:10.1007/s00508-020-01777-9.
   PubMed Web of Science ®Google Scholar
• Bhavsar AB, Olbrecht J, Izurieta P. Pin33 cost-effectiveness of current pneumococcal vaccines in older adults in european settings: a systematic literature review. Value Health. 2019;22:S645. doi:10.1016/j.jval.2019.09.1277.
   Google Scholar
• Birck AM, Nordin Christensen L, Pedersen MH, Olsen J, Johnson KD, Bencina G, Clausen TH, Larsen CS. Health economic evaluation of introducing a PPSV23-based vaccination programme to adults aged 65 and above, and an extension to the 60-64 age group in Denmark. Expert Rev Vaccines. 2021;20(10):1327–37. doi:10.1080/14760584.2021.1977627.
   PubMed Web of Science ®Google Scholar
• Boccalini S, Bechini A, Gasparini R, Panatto D, Amicizia D, Bonanni P. Economic studies applied to vaccines against invasive diseases: an updated budget impact analysis of age-based pneumococcal vaccination strategies in the elderly in Italy. Hum Vaccin Immunother. 2017;13(2):417–22. doi:10.1080/21645515.2017.1264827.
   PubMed Web of Science ®Google Scholar
• Butić I, Gužvinec M, Jelić M, Groš I, Lucić S, Bošnjak M, Tambić Andrašević A. Serotype distribution and antimicrobial resistance of invasive Streptococcus pneumoniae isolates among Croatian adults during a fifteen year period (2005-2019). Croat Med J. 2022;63(2):156–65. doi:10.3325/cmj.2022.63.156.
   PubMed Web of Science ®Google Scholar
• CFV. Eidgenössische Kommission für Impffragen Protokoll der 88. Plenarsitzung. 2022.
   Google Scholar
• Constantinou CA, Ziogas DC, Venetsanopoulou A, Gamaletsou MN, Koutsogeorgopoulou L, Barbouni A, Tzioufas AG, Sipsas NV. A clinical audit of pneumococcal vaccination among patients with autoimmune rheumatic diseases living in Greece: the power of awareness. Vaccine. 2021;39(11):1593–7. doi:10.1016/j.vaccine.2021.02.009.
   PubMed Web of Science ®Google Scholar
• Contou D, Coudroy R, Colin G, Tadié J-M, Cour M, Sonneville R, Mekontso Dessap A, de Prost N. Pneumococcal purpura fulminans in asplenic or hyposplenic patients: a French multicenter exposed-unexposed retrospective cohort study. Crit Care. 2020;24(1):1–8. doi:10.1186/s13054-020-2769-y.
   PubMed Web of Science ®Google Scholar
• Council SH. Avis 9674 - Vaccination antipneumococcique (adultes). 2022.
   Google Scholar
• CSMI. Infections invasives à Pneumocoques. 2022.
   Google Scholar
• De Burghgraeve T, Henrard S, Verboven B, Van Pottelbergh G, Vaes B, Mathei C. The incidence of lower respiratory tract infections and pneumococcal vaccination status in adults in Flemish primary care. Acta Clin Belg. 2021;76(5):335–45. doi:10.1080/17843286.2020.1735113.
   PubMed Web of Science ®Google Scholar
• de Vries L, Kellerborg K, Brouwer W, van Baal P. Don’t forget about the future: The impact of including future costs on the cost-effectiveness of adult pneumococcal conjugate vaccination with PCV13 in the Netherlands. Vaccine. 2021;39(29):3834–43. doi:10.1016/j.vaccine.2021.05.091.
   PubMed Web of Science ®Google Scholar
• DGS. Programa nacional de vacinação. 2022.
   Google Scholar
• Esposito S, Franco E, Gavazzi G, de Miguel AG, Hardt R, Kassianos G, Bertrand I, Levant M-C, Soubeyrand B, López Trigo JA, et al. The public health value of vaccination for seniors in Europe. Vaccine. 2018;36(19):2523–8. doi:10.1016/j.vaccine.2018.03.053.
   PubMed Web of Science ®Google Scholar
• Garcia Garrido HM, Mak AM, Wit FW, Wong GW, Knol MJ, Vollaard A, Tanck MWT, Van Der Ende A, Grobusch MP, Goorhuis A, et al. Incidence and risk factors for invasive pneumococcal disease and community-acquired pneumonia in human immunodeficiency virus–infected individuals in a high-income setting. Clin Infect Dis. 2020;71(1):41–50. doi:10.1093/cid/ciz728.
   PubMed Web of Science ®Google Scholar
• Giuffrida S. Calabria: a successful experience implementing herpes zoster vaccination strategies. Aging Clin Exp Res. 2019;31(3):421–3. doi:10.1007/s40520-019-01145-2.
   PubMed Web of Science ®Google Scholar
• Gomez SC, Jiang Y, Lu X, Pulfer GN, Boix PR. Pin44-economic evaluation of 60+ years adult vaccination strategy using pneumococcal polysaccharide vaccine in Spain. Value Health. 2018;21:S228. doi:10.1016/j.jval.2018.09.1363.
   Web of Science ®Google Scholar
• Gouveia M, Jesus G, Inês M, Costa J, Borges M. Cost-effectiveness of the 13-valent pneumococcal conjugate vaccine in adults in Portugal versus “no vaccination” and versus vaccination with the 23-valent pneumococcal polysaccharide vaccine. Hum Vaccin Immunother. 2019;15(4):850–8. doi:10.1080/21645515.2018.1560769.
   PubMed Web of Science ®Google Scholar
• Guerrini G, Franzetti F, Giacomelli R, Meroni L, Riva A, Scirè CA, Scrivo R, Tavio M, Agostinone A, Airò P, et al. Italian recommendations for influenza and pneumococcal vaccination in adult patients with autoimmune rheumatic diseases. Clin Exp Rheumatol. 2019;38(2):245–56. doi:10.55563/clinexprheumatol/hj69ne.
   PubMed Web of Science ®Google Scholar
• HAS. Vaccination contre les infections à pneumocoque en contexte de pénurie de vaccin pneumococcique non conjugué 23-valent. 2017.
   Google Scholar
• HCSP. Infections à pneumocoque : recommandations vaccinales pour les adultes. 2017.
   Google Scholar
• Folkehelseinstituttet. Pneumokokkvaksine til risikogrupper. 2020.
   Google Scholar
• Health M. Farmako-ekonomický rozbor lieku. 2017.
   Google Scholar
• Horvat M, Robnik B, Bizjak K, Vuzem S, Miksić NG. Audit of post-splenectomy prophylaxis in a single tertiary center in Slovenia: where are we and what should be done? Surg Infect (Larchmt). 2021;22(3):292–8. doi:10.1089/sur.2020.038.
   PubMed Web of Science ®Google Scholar
• INSP. Luna Națională a informării despre VACCINARE aprilie 2022. 2022.
   Google Scholar
• ISS. Guida alla controindicazioni. 2018.
   Google Scholar
• JCVI. Minute of the JCVI pneumococcal sub-committee meeting 2022.
   Google Scholar
• Kopp A, Mangin O, Gantzer L, Lekens B, Simoneau G, Ravelomanantsoa M, Evans J, Bergmann JF, Sellier P. Pneumococcal vaccination coverage in France by general practitioners in adults with a high risk of pneumococcal disease. Hum Vaccin Immunother. 2021;17(1):162–9. doi:10.1080/21645515.2020.1756669.
   PubMed Web of Science ®Google Scholar
• Kuchenbecker U, Chase D, Reichert A, Schiffner-Rohe J, Atwood M, Ortiz JR. Estimating the cost-effectiveness of a sequential pneumococcal vaccination program for adults in Germany. PloS One. 2018;13(5):e0197905. doi:10.1371/journal.pone.0197905.
   PubMed Web of Science ®Google Scholar
• Landlaeknir DoHE. Pneumokokkasýking, ífarandi. 2019.
   Google Scholar
• Larsen L, Bistrup C, Sørensen SS, Boesby L, Nguyen MTT, Johansen IS. The coverage of influenza and pneumococcal vaccination among kidney transplant recipients and waiting list patients: a cross‐sectional survey in Denmark. Transpl Infect Dis. 2021;23(3):e13537. doi:10.1111/tid.13537.
   PubMed Web of Science ®Google Scholar
• Maraki S, Mavromanolaki VE, Stafylaki D, Hamilos G, Samonis G. The evolving epidemiology of serotype distribution and antimicrobial resistance of streptococcus pneumoniae strains isolated from adults in Crete, Greece, 2009–2016. Infect Chemother. 2018;50(4):328–39. doi:10.3947/ic.2018.50.4.328.
   PubMed Web of Science ®Google Scholar
• Marbaix S, Peetermans WE, Verhaegen J, Annemans L, Sato R, Mignon A, Atwood M, Weycker D. Cost-effectiveness of PCV13 vaccination in Belgian adults aged 65-84 years at elevated risk of pneumococcal infection. PloS One. 2018;13(7):e0199427. doi:10.1371/journal.pone.0199427.
   PubMed Web of Science ®Google Scholar
• Matthews I, Lu X, Xia Q, Black W, Nozad B. Pneumococcal vaccine coverage among individuals aged 18 to 64 years old with underlying medical conditions in the UK: a retrospective database analysis. BMC Public Health. 2020;20(1):1–0. doi:10.1186/s12889-020-09613-5.
   PubMed Web of Science ®Google Scholar
• McCarthy H, Jackson M, Corcoran M, McElligott M, MacHale E, Sulaiman I, Cushen B, Costello RW, Humpreys H. Colonisation of Irish patients with chronic obstructive pulmonary disease by Streptococcus pneumoniae and analysis of the pneumococcal vaccine coverage: a non-interventional, observational, prospective cohort study. BMJ Open. 2017;7(7):e013944. doi:10.1136/bmjopen-2016-013944.
   PubMed Web of Science ®Google Scholar
• Mertsch P, Rademacher J, de Roux A, Barten G, Diel R, Gert E, Naim J, Zurawski A, Welte T, Ringshausen FC. PROGNOSIS-the German bronchiectasis registry: first results. Eur Respiratory Soc. 2017;50(61):PA4059.
   Web of Science ®Google Scholar
• Wróbel I, Kuch A, Waśko I, Gołębiewska A, Ronkiewicz P, Kiedrowska M, et al. Postępy Mikrobiologii - Invasive pneumococcal disease among patiens above 65 years old. Polskie towarzystwo mikrobiologów. 2017;56(3):42.
   Google Scholar
• Mohr A, Plentz A, Sieroslawski A, Pezenburg F, Koch M, Bauernfeind S, Pfeifer M, Salzberger B, Hitzenbichler F. Adherence to STIKO recommendations in patients with pulmonary disease in southeast Germany. Infection. 2021;49(6):1319–23. doi:10.1007/s15010-021-01708-4.
   PubMed Web of Science ®Google Scholar
• Monier A, Puyade M, Hernanz MG, Bouchaert P, Leleu X, Tourani J, Roblot F, Rammaert B. Observational study of vaccination in cancer patients: how can vaccine coverage be improved? Médecine et Maladies Infectieuses. 2020;50(3):263–8. doi:10.1016/j.medmal.2019.11.006.
   PubMed Web of Science ®Google Scholar
• Ng WL, Anjum A, Sebastian A, Devlin J, Fraser A. P04 A quality improvement initiative to improve influenza and pneumococcal vaccination rates in patients receiving biological DMARDS (bDMARDs) in the mid-west of Ireland. Rheumatology. 2020;59(Supplement_2):keaa111. 003. doi:10.1093/rheumatology/keaa111.003.
   Google Scholar
• Office NI. Pneumococcal infection. 2018:1–12.
   Google Scholar
• Papagiannis D, Rachiotis G, Mariolis A, Zafiriou E, Gourgoulianis KI. Vaccination coverage of the elderly in Greece: a cross-sectional nationwide study. Can J Infect Dis Med Microbiol. 2020;2020. doi:10.1155/2020/5459793.
   PubMed Web of Science ®Google Scholar
• Paparoupa M. Pneumokokken-Impfung im Erwachsenenalter. Praevention und Rehab. 2017;29:106.
   Google Scholar
• Piotrowska A, Paradowska-Stankiewicz I, Skarżyński H. Rates of vaccination against Streptococcus pneumoniae in cochlear implant patients. Med Sci Monit. 2017;23:4567. doi:10.12659/MSM.903188.
   PubMed Web of Science ®Google Scholar
• Popova A, Shipulina O, Dmitryukova M, Deulina M, Pokrovsky V. Results of HPV testing for anal screening in men who have sex with men. J Int AIDS Soc. 2018;21:180–.
   Web of Science ®Google Scholar
• PSC. Priporočila za cepljenje odraslih in otrok, starih 5 let in več, proti pnevmokoknim okužbam. 2019.
   Google Scholar
• PSC. Povzetek glavnih značilnosti zdravila. 2021.
   Google Scholar
• Ratera. Vaccination of adults.
   Google Scholar
• RIVM. Monitor Vaccinatiegraad Nationaal Programma Pneumokokkenvaccinatie Volwassenen (NPPV). 2020.
   Google Scholar
• RIVM. Pneumokokkenvaccinatie Factsheet. 2022.
   Google Scholar
• RIVM. Pneumokokkenziekte Richtlijn. 2022.
   Google Scholar
• Rozenbaum M, editor. 1434. Cost-effectiveness of sequencial vaccination with the 13-valent pneumococcal conjugate vaccine (PCV13) followed by the 23 valent polysaccharide vaccine (PPV23) in the Netherlands. Open Forum Infectious diseases. USA: Oxford University Press; 2018. p. S443–S444.
   Google Scholar
• Rozenbaum M, editor. 1439. The cost-effectiveness of vaccinating adults at increased risk of pneumococcal disease against pneumococcal disease in the Netherlands. Open Forum Infectious diseases. USA: Oxford University Press; 2018. p. S445.
   Google Scholar
• Runyo F, Matignon M, Audureau E, Vindrios W, Boueilh A, Gomart C, Grimbert P, Gallien S, Melica G. Infectious disease consultation is effective in boosting vaccine coverage in patients awaiting kidney transplantation: a French prospective study. Transpl Infect Dis. 2021;23(4):e13607. doi:10.1111/tid.13607.
   PubMedGoogle Scholar
• Sanduzzi A, Canora A, Belfiore P, Bocchino M, Liguori R, Liguori G. Impact of 13Valent vaccine for Prevention of pneumococcal diseases in children and adults at risk: possible scenarios in Campania region. Infectious disorders-drug targets (formerly Current drug targets-Infectious disorders). Infect Disord Drug Targets. 2019;19(4):403–8. doi:10.2174/1871526518666180820161630.
   PubMedGoogle Scholar
• Schmedt N, Schiffner-Rohe J, Sprenger R, Walker J, von Eiff C, Häckl D, Gopichandran V. Pneumococcal vaccination rates in immunocompromised patients—a cohort study based on claims data from more than 200,000 patients in Germany. PloS One. 2019;14(8):e0220848. doi:10.1371/journal.pone.0220848.
   PubMed Web of Science ®Google Scholar
• Sevilla J, Stawasz A, Burnes D, Poulsen P, Sato R, Bloom D. Calculating the indirect costs of adult pneumococcal disease and the rate of return to the 13-valent pneumococcal conjugate vaccine (PCV13) in older adults, with an application to Denmark. Value Health. 2017;20(9):A787. doi:10.1016/j.jval.2017.08.2302.
   Web of Science ®Google Scholar
• SSI. Pneumokokvaccine 23-valent (Pneumovax). 2022.
   Google Scholar
• SST. Tilbud om pneumokokvaccination til særlige risikogrupper. 2020.
   Google Scholar
• SST. Tilskud til vacciner til visse persongrupper. 2022.
   Google Scholar
• Sticchi L, Taramasso L, Di Biagio A, Olobardi D, Icardi G, Bassetti M. Will vaccine hesitancy compromise our efforts to face the next SARS-CoV-2 epidemic wave? Hum Vaccin Immunother. 2021;17(6):1664–5. doi:10.1080/21645515.2020.1829413.
   PubMed Web of Science ®Google Scholar
• Storch J, Fleischmann-Struzek C, Rose N, Lehmann T, Mikolajetz A, Maddela S, Pletz MW, Forstner C, Wichmann O, Neufeind J, et al. The effect of influenza and pneumococcal vaccination in the elderly on health service utilisation and costs: a claims data-based cohort study. Eur J Health Econ. 2022;23(1):67–80. doi:10.1007/s10198-021-01343-8.
   PubMed Web of Science ®Google Scholar
• Suitner C, Salvador Casara BG, Maggi S, Baldo V. An independent study to compare compliance, attitudes, knowledge, and sources of knowledge about pneumococcal vaccinations among an Italian sample of older adults. Vaccines. 2022;10(4):490. doi:10.3390/vaccines10040490.
   Web of Science ®Google Scholar
• Tavares J, Cruz AR, Nogueira R. Chronic obstructive pulmonary disease–are we vaccinating the patients? Eur Respiratory Soc; 2017.
   Google Scholar
• THL (Finnish Institute for Health and Welfare). Pneumokokkirokotusstrategiat. 2018; 1–52.
   Google Scholar
• THL (Finnish Institute for Health and Welfare). Riskiryhmien pneumokokkirokotukset. 2022.
   Google Scholar
• Thorrington D, Van Rossum L, Knol M, De Melker H, Rümke H, Hak E, Van Hoek AJ. Impact and cost-effectiveness of different vaccination strategies to reduce the burden of pneumococcal disease among elderly in the Netherlands. PloS One. 2018;13(2):e0192640. doi:10.1371/journal.pone.0192640.
   PubMed Web of Science ®Google Scholar
• Tubiana S, Labarere J, Levraut J, Michelet P, de Vaux FJ, Doumenc B, Hausfater P, Choquet C, Plaisance P, Schmidt J, et al. Effectiveness of a multifaceted informational-based and text message reminders on pneumococcal and influenza vaccinations in hospital emergency departments: a cluster-randomized controlled trial. Vaccines. 2021;9(9):962. doi:10.3390/vaccines9090962.
   Web of Science ®Google Scholar
• ULAC. The number of people vaccinated against pneumococcal infection has increased. 2021.
   Google Scholar
• VACSATC. FELNŐTTEKNEK AJÁNLOTT VÉDŐOLTÁSOK. 2017.
   Google Scholar
• Vila-Córcoles A, Ochoa-Gondar O, de Diego C, Satué E, Vila-Rovira A, Aragón M. Pneumococcal vaccination coverages by age, sex and specific underlying risk conditions among middle-aged and older adults in Catalonia, Spain, 2017. Eurosurveillance. 2019;24(29):1800446. doi:10.2807/1560-7917.ES.2019.24.29.1800446.
   Web of Science ®Google Scholar
• Walter E, Eichhober G, Voit M. Pin32 - a public health and budget impact analysis (BIA) of vaccinating adults against pneumococcal-diseases in austria. Value Health. 2019;22:S645. doi:10.1016/j.jval.2019.09.1276.
   Web of Science ®Google Scholar
• Weinmayr L-M, Steinhäuser J, Gehring SC, Goetz K. Vaccination management for elderly patients in primary care settings–documentation and responsibilities during a vaccination campaign. Patient Prefer Adherence. 2019;13:1295. doi:10.2147/PPA.S212507.
   PubMed Web of Science ®Google Scholar
• Willem L, Blommaert A, Hanquet G, Thiry N, Bilcke J, Theeten H, Verhaegen J, Goossens H, Beutels P. Economic evaluation of pneumococcal vaccines for adults aged over 50 years in Belgium. Hum Vaccin Immunother. 2018;14(5):1218–29. doi:10.1080/21645515.2018.1428507.
   PubMed Web of Science ®Google Scholar
• Wolff E, Storsaeter J, Örtqvist Å, Naucler P, Larsson S, Lepp T, Roth A. Cost-effectiveness of pneumococcal vaccination for elderly in Sweden. Vaccine. 2020;38(32):4988–95. doi:10.1016/j.vaccine.2020.05.072.
   PubMed Web of Science ®Google Scholar
• Wyplosz B, Fernandes J, Sultan A, Roche N, Roubille F, Loubet P, Fougère B, Moulin B, Duhot D, Vainchtock A, et al. Pneumococcal and influenza vaccination coverage among at-risk adults: A 5-year French national observational study. Vaccine. 2022;40(33):4911–21. doi:10.1016/j.vaccine.2022.06.071.
   PubMed Web of Science ®Google Scholar
• Zeevat F, Boersma W, van der Schans J, Boersma C, Postma M. Pin65 cost-effectiveness analysis on elderly pneumococcal vaccination in the netherlands: challenging the dutch health council’s advice. Value Health. 2019;22:S650. doi:10.1016/j.jval.2019.09.1306.
   Web of Science ®Google Scholar
• Zeevat F, van der Schans J, Boersma W, Boersma C, Postma MJ. Cost-effectiveness analysis on elderly pneumococcal vaccination in the Netherlands: challenging the Dutch health Council’s advice. Vaccine. 2019;37(43):6282–4. doi:10.1016/j.vaccine.2019.08.051.
   PubMed Web of Science ®Google Scholar
• Zorginstituut. Vaccinatie pneumokokken 60-plussers buiten Zorgverzekeringswet om financieren. 2018.
   Google Scholar
• Zorginstituut. Verslag van de vergadering van de Wetenschappelijke Adviesraad (WAR) over 13-valente pneumokokken-polysacharidenconjugaatvaccin (Prevenar®). 2021.
   Google Scholar
• (CDC) CfDCaP. Use of 15-valent pneumococcal conjugate vaccine and 20-valent pneumococcal conjugate vaccine among U.S. Adults: updated recommendations of the advisory committee on immunization practices — United States, 2022. USA: CDC; 2022. 2022 Jan 28; 71(4):109–17. doi:10.15585/mmwr.mm7104a1.
   Google Scholar
• Department of Health and Aged Care (Australia). Pneumococcal vaccination for all Australians Australia. 2023. https://immunisationhandbook.health.gov.au/resources/publications/pneumococcal-vaccination-for-all-australians#:~:text=Children%20over%2012%20months%2C%20adolescents,at%20least%205%20years%20later.
   Google Scholar
• Ministry of Health LaW厚. Pneumococcal infection (elderly) Japan. 2023. https://www.mhlw.go.jp/stf/seisakunitsuite/bunya/kenkou_iryou/kenkou/kekkaku-kansenshou/haienkyukin/index_1.html.
   Google Scholar
• Populationpyramid.net. Population pyramids of the world from 1950 to 2100: Austria. 2022. https://www.populationpyramid.net/austria/2022/.
   Google Scholar
• Wasserman MD, Perdrizet J, Grant L, Hayford K, Singh S, Saharia P, Horn, EK, Farkouh, RA. Clinical and economic burden of pneumococcal disease due to serotypes contained in Current and investigational pneumococcal conjugate vaccines in children under five years of age. Infect Dis Ther. 2021;10(4):2701–20. doi:10.1007/s40121-021-00544-1.
   PubMed Web of Science ®Google Scholar
• Kwambana-Adams B, Hanson B, Worwui A, Agbla S, Foster-Nyarko E, Ceesay F, Ebruke C, Egere U, Zhou Y, Ndukum M, Sodergren E. Rapid replacement by non-vaccine pneumococcal serotypes may mitigate the impact of the pneumococcal conjugate vaccine on nasopharyngeal bacterial ecology. Sci Rep. 2017;7(1):8127. doi:10.1038/s41598-017-08717-0.
   PubMedGoogle Scholar
• Yoon JG, Jang AY, Kim MJ, Seo YB, Lee J, Choi YH, Kim YK, Jeong EJ, Kim HS, Kwon KT, et al. Persistent serotype 3 and 19A invasive pneumococcal diseases in adults in vaccine era: Serotype-dependent difference in ceftriaxone susceptibility. Vaccine. 2022;40(15):2258–65. doi:10.1016/j.vaccine.2022.03.004.
   PubMed Web of Science ®Google Scholar
• Janssens E, Flamaing J, Vandermeulen C, Peetermans WE, Desmet S, De Munter P. The 20-valent pneumococcal conjugate vaccine (PCV20): expected added value. Acta Clin Belg. 2023;78(1):78–86. doi:10.1080/17843286.2022.2039865.
   PubMed Web of Science ®Google Scholar
• Løchen A, Croucher NJ, Anderson RM. Divergent serotype replacement trends and increasing diversity in pneumococcal disease in high income settings reduce the benefit of expanding vaccine valency. Sci Rep. 2020;10(1):18977. doi:10.1038/s41598-020-75691-5.
   PubMed Web of Science ®Google Scholar
• Mungall BA, Hoet B, Nieto Guevara J, Soumahoro L. A systematic review of invasive pneumococcal disease vaccine failures and breakthrough with higher-valency pneumococcal conjugate vaccines in children. Expert Rev Vaccines. 2022;21(2):201–14. doi:10.1080/14760584.2022.2012455.
   PubMed Web of Science ®Google Scholar